3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Lymphoma, Follicular
4
Lymphoma, Non-Hodgkin
3
Pancreatic Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Waldenstrom Macroglobulinemia
1
Virus Diseases
1
Uterine Cervical Neoplasms
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Endometrial Neoplasms
1
Disease
1
Burkitt Lymphoma
1
Interventions
Prednisone
3
pembrolizumab
2
Melphalan
2
Cytarabine
2
venetoclax
1
ofatumumab
1
obinutuzumab
1
ioflupane
1
imetelstat
1
ibrutinib
1
gossypol acetic acid
1
gilteritinib
1
fluorocholine
1
fluciclovine F-18
1
deltacortene
1
daratumumab
1
aflibercept
1
abiraterone
1
Temozolomide
1
Self-Management
1
Quality of Life
1
Professional Autonomy
1
Paclitaxel
1
Oncolytic Virotherapy
1
Octreotide
1
Mitoxantrone
1
Methylene Blue
1
Lenalidomide
1
Gemtuzumab
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled